New DHL report sees transformational trends
Credit: DHL
While R&D scientists and medical researchers are blazing new trails into areas like cellular therapy and genomics, the folks managing life sciences and healthcare supply chains are dealing with their own revolutions in patient care, new forms of drug delivery and new regulatory systems. Some of this thinking shows up in a new report from DHL, whose Life Sciences and Healthcare unit is the leading provider of global logistics services to the sector. There are six trends it highlights, and while the data behind the trend reporting is somewhat subjective, these trends should give pharma supply chain managers some guidance on what to expect from their logistics functions. The six are:
In announcing the report, Scott Allison, president, life sciences and healthcare, DHL Customer Solutions & Innovation, said, “We are only just beginning to understand the huge changes the Life Sciences sector is facing in terms of how patients are diagnosed and treated, what new care challenges it faces, and the technology-driven tools to address them. DHL’s new report focuses on the transformation in the way medical products and services are produced, distributed and consumed. It is clear that logistic providers have a key role to play in this transformation to deliver healthcare to the world with cost-effective, agile and highly responsive supply chains.”
The report,
The Future of Life Sciences and Healthcare Logistics
, is downloadable at www.dhl.com/futurelsh.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.